Conclusion
The SARS-CoV-2 virus, which is the cause of COVID-19 infection, has the ability to reduce several parts of the brain. Axonal and transsynaptic transport are most likely used by the virus to reach the CNS through the olfactory nerve. The second way the virus might enter the brain is the hematogenous route. According to prior study, COVID-19 infection can negatively affect glial cells, which leads to negative side effects such agitation, altered consciousness, headaches, and dizziness, or even mental and neurodegenerative disorders. 
Paxlovid has been approved by FDA in the treatment of COVID-19 infection. The findings suggest that Paxlovid diminishes not only the risk of hospitalization or death from a coronavirus infection but also the risk of long-term illness.